Skip to content

US · ADGM · MEDICAL - DEVICES

Adagio Medical Holdings, Inc. (ADGM) intrinsic value and stock valuation

$1.75as of 2026-11-21 · Mkt cap 15.18M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Adagio Medical Holdings, Inc. DCF and intrinsic value

InvestorsCraft values ADGM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ADGM’s statements →

Adagio Medical Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Laguna Hills, CA 92653 adagiomedical.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-25.08M
20202025
Free cash flow
-$-19.39M
20212025
Total equity
$12.4M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$270K$300K$190K$270K
Operating income-$-21.89M-$-62.48M-$-27.94M-$-23.91M-$-20.64M
Net income-$-25.08M-$-53.76M-$-38.15M-$-23.67M-$-19.94M
EPSd-$-1.51M-$-3.54M-$-4.85M-$-1.23M-$-1.04M
Operating cash flow-$-19.01M-$-29.46M-$-25.65M-$-22.41M-$-19.31M
Capital expenditure-$-370K-$-1.65M-$-330K-$-490K-$-1.27M
Free cash flow-$-19.39M-$-31.11M-$-25.98M-$-22.9M-$-20.58M
Total assets$43.3M$48.5M$6.83M$8.7M$21.4M
Total debt$21.8M$16.3M$38.4M$9.8M$0.00
Net debt$4.65M-$-4.32M$37M$4.25M-$-18.85M
Total equity$12.4M$19.9M-$-132.02M-$-95.88M-$-72.62M
Cash and short-term investments$17.1M$20.6M$1.38M$5.55M$18.9M
Income statement
20252024202320222021
Revenue$0.00$270K$300K$190K$270K
Cost of revenue$680K$1.94M$1.31M$880K$1.16M
Gross profit-$-680K-$-1.67M-$-1.01M-$-690K-$-890K
Research and development expenses$10.6M$4.63M$15.4M$17.9M$15.4M
Selling, general and administrative expenses$10.6M$6.98M$11.5M$5.37M$4.4M
Other expenses$0.00$49.2M$0.00$0.00$0.00
Operating expenses$21.2M$60.8M$26.9M$23.2M$19.8M
Cost and expenses$21.9M$62.8M$28.2M$24.1M$20.9M
Interest income$480K$420K$0.00$40K$0.00
Interest expense$2.91M-$-1.1M$1.66M$140K$0.00
Depreciation and amortization$970K$1.39M$530K$490K$340K
Ebitda-$-21.21M-$-53.48M-$-35.95M-$-23.04M-$-19.6M
Operating income-$-21.89M-$-62.48M-$-27.94M-$-23.91M-$-20.64M
Total other income/expenses, net-$-3.19M$8.72M-$-10.2M$240K$710K
Income before tax-$-25.08M-$-53.76M-$-38.15M-$-23.67M-$-19.94M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-25.08M-$-53.76M-$-38.15M-$-23.67M-$-19.94M
Weighted average shares outstanding$16.6M$15.2M$7.86M$19.2M$19.2M
Weighted average diluted shares outstanding$16.6M$15.2M$7.86M$19.2M$19.2M
Balance sheet
20252024202320222021
Cash and short-term investments$17.1M$20.6M$1.38M$5.55M$18.9M
Net receivables$0.00$40K$70K$0.00$30K
Inventory$1.67M$2.57M$3.32M$370K$330K
Total current assets$20.1M$25.4M$5.18M$6.73M$19.7M
Property, plant and equipment, net$2.23M$2.15M$1.62M$1.94M$1.7M
Goodwill and intangible assets$20.9M$20.9M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$23.2M$23.1M$1.64M$1.97M$1.72M
Total assets$43.3M$48.5M$6.83M$8.7M$21.4M
Accounts payable$1.08M$2.84M$3.83M$1.01M$580K
Short-term debt$150K$140K$38.2M$9.66M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.23M$7.76M$47.2M$13M$2.59M
Long-term debt$21.6M$16.1M$200K$130K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.6M$20.8M$91.7M$91.6M$91.5M
Capital lease obligations$720K$50K$130K$300K$0.00
Total liabilities$30.9M$28.5M$138.9M$104.6M$94.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-95.61M-$-70.59M-$-133.65M-$-97.06M-$-73.39M
Accumulated other comprehensive income (loss)-$-100K$0.00$20K$30K$0.00
Total equity$12.4M$19.9M-$-132.02M-$-95.88M-$-72.62M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$21.8M$16.3M$38.4M$9.8M$0.00
Net debt$4.65M-$-4.32M$37M$4.25M-$-18.85M
Cash flow statement
20252024202320222021
Net income-$-25.08M-$-75.04M-$-36.59M-$-23.67M-$-19.94M
Depreciation and amortization$970K$1.39M$550K$490K$340K
Stock-based compensation$1.48M$0.00$440K$360K$340K
Change in working capital$2.66M$5.79M-$-30K$330K$580K
Accounts receivable$40K$40K-$-70K$30K$40K
Inventory$930K$630K-$-2.98M$40K-$-470K
Accounts payable-$-1.76M-$-4.56M$2.82M$440K$280K
Net cash provided by operating activities-$-19.01M-$-29.46M-$-25.65M-$-22.41M-$-19.31M
Investments in property, plant and equipment-$-370K-$-1.65M-$-330K-$-500K-$-1.26M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-370K-$-1.65M-$-340K-$-500K-$-1.27M
Common stock issued$16.1M$0.00$0.00$30K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.1M$15.6M$21.9M$9.53M$130K
Net change in cash-$-3.48M$20.6M-$-4.16M$5.05M-$-20.38M
Cash at end of period$17.1M$20.6M$1.38M$5.55M$18.9M
Operating cash flow-$-19.01M-$-29.46M-$-25.65M-$-22.41M-$-19.31M
Capital expenditure-$-370K-$-1.65M-$-330K-$-490K-$-1.27M
Free cash flow-$-19.39M-$-31.11M-$-25.98M-$-22.9M-$-20.58M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Adagio Medical Holdings, Inc.

        Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.

        CEO
        Todd Usen
        Employees
        41
        Beta
        -0.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Adagio Medical Holdings, Inc. (ADGM)?

        InvestorsCraft does not currently publish an intrinsic value for ADGM. How the IC value is calculated.

        Is ADGM undervalued?

        InvestorsCraft does not publish an undervaluation signal for ADGM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.